1stOncology covers the latest development on more than 560 bispecific antibodies (also including ADCs and adoptive cell therapies) and over 85 different combination therapy trials of these in oncology. These emerging therapies are showing exciting results through the many designs and strategies that are currently being developed to fight cancer. 1stOncology will help you to explore the engineering finesse employed in the development of these therapies, as well as the ongoing results from the clinic.
Moreover, 1stOncology provides unique insights to novel targeting strategies among the more than one thousand targets of biotherapeutics in cancer drug development. In 1stOncology you can easily explore the strategies for intracellular and membrane-bound targets, delivery and activation approaches, mitigating off-target effects etc.
Hence, 1stOncology is a valuable tool to evaluate developing biotherapeutics such as bispecific antibodies and more for new indications and targets. Sign up for your free 30 minutes consultation below.